Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend your doctor by getting a second opinion? In this segment, Dr. Brady Stein and Dr. Naveen Pemmaraju, both experts at academic medical centers, weigh in on this important decision. The doctors share their perspective on second opinions, why it matters with rare conditions, and advice for how to seek consultation with another doctor. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Author: Editor
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy.
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients with EGFR mutation-positive NSCLC.
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative chemotherapy is the standard of care. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg argues that there is not a role for the surgical management of metastatic neuroendocrine cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Michael A. Choti argues that there is a role for surgical management of metastatic neuroendocrine cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state of knowledge regarding hereditary syndromes in GI cancer, and proffers who should be tested and why. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update on novel therapies for GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the treatment of colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Neil H. Segal provides an update on the use of immunotherapy in the treatment of GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler provides an update on the role of aspirin therapy in both GI cancer survivors and the general population. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC.
Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium explored updated standards of care for treatment sequencing for pancreatic carcinoma. Utilizing a case based approach, this activity assesses the use of adjuvant chemotherapy at relapse, examines the optimal approach for patients with borderline resectable disease, and probes how the management of locally advanced pancreatic cancer impacts treatment decisions in the metastatic setting. This symposium was organized by: Celgene International SÃ rl. Activity Disclaimer This satellite symposium was held in conjunction with the ESMO 19th World Congress on Gastrointestinal Cancer. The…
Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and the clinic lead to better clinical outcomes, including longer overall survival.
K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN discusses how a new study highlights how estrogen could potentially be protective for some forms of cancers including esophageal cancer. See Report Below: Female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published online today in The Annals of Thoracic Surgery. Esophageal cancer is one of the deadliest cancers in the world, said…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the next steps for the preclinical models of GKT831
Hagop M. Kantarjian, MD of MD Anderson Cancer Center goes over some possible next steps for Inotuzumab after it has received FDA approval for acute
Hagop M. Kantarjian, MD of MD Anderson Cancer Center discusses how veno occlusive disease may cause complications while using inotuzumab if not identitified in adult acute lymphoblastic leukemia patients.
Hagop M. Kantarjian, MD of MD Anderson Cancer Center states “We are witnessing a slow motion revolution in ALL” talking about Inotuzumab.
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the relatively well tolerated GKT831 in other disease states.
K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published in The Annals of Thoracic Surgery. Study Results Below: Esophageal cancer is one of the deadliest cancers in the world, said senior author K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN. It affects men and women differently. Men are more…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and notes that inhibiting CAFs are not sufficient to stop cancer growth.
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the median survival rate nearly doubles combining Inotuzumab with chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Professor Gareth Thomas of University of Southampton discusses data in multiple preclinical models that showed GKT831 efficiently targeted cancer associated fibroblasts (CAFs) and delayed tumor growth.
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in progression-free survival with an IT combination.
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.
Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that the PACIFIC trial of durvalumab after chemo/radiation is positive for a significant improvement in progression-free survival.
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia gives the trial overview and conclusions of Pfizer’s newly approved FDA CD22-directed antibody-drug conjugate Besponsa (Inotuzumab Ozogamicin) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Srdan Verstovsek discusses the clinical data relevant to the use of opeginterferon for patients with polycythemia vera. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Elizabeth O. Hexner discusses when to move from hydroxyurea to a second-line therapy. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Brady Lee Stein discusses whether our current understanding of the prognostication and initiation of therapy for PV patients is correct. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.
In this discussion, recorded during the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 4-5, 2017 in Philadelphia, the Congress co-chairs highlight the key points presented during the meeting, with the aim of sharing updates that will help you enhance your clinical practice. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7260 © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that there is no standard second line therapy for the treatment of hepatocellular carcinoma (HCC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should be the standard second line therapy for hepatocellular carcinoma (HCC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Mark A, Schattner provides an update into the novel endoscopic management of pancreatic biliary cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eileen O’Reilly provides an update in novel targeted therapy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine is the optimal adjuvant chemotherapy regimen for resected pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that gemcitabine/nab-paclitaxel is the optimal adjuvant chemotherapy for resected pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative chemotherapy plus radiation is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that chemotherapy alone is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that surgery is not required after chemoradiotherapy for squamous cancer of the esophagus. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that post-operative radition therapy is required in this setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
At a recent town meeting in partnership with Robert H. Lurie Comprehensive Cancer Center in Chicago, Dr. Brady Stein helps viewers understand what should be considered when choosing a treatment plan for those with essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). Dr. Stein talks about factors such as symptoms and risk. He goes on to provide considerations for each of the myeloproliferative neoplasms (MPNs).Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/ +patientpowerinfo Â
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa provides an update in novel treatments for hepatocellular carcinoma (HCC) in the era of hepatitis C therapies. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Umberto Ricardi discusses the use of loco-regional therapy to treat brain metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.